According to a report by Future Market Insights, the global interleukin-6, Il6-inhibitors market size is predicted to reach US$ 93.3 billion by 2033, with a compound annual growth rate of 10.9%.
Interleukin-6 (IL-6) inhibitors, a proinflammatory cytokine, is produced by different types of cell which includes monocytes, fibroblasts and lymphocytes. The demand for immune-based therapies is increasing due to their effectiveness in treating various diseases. Interleukin-6 (IL-6) inhibitors has shown promising result in treating serious COVID-19 cases. IL-6 inhibitors are also used widely for the treatment of rheumatoid arthritis. Increasing prevalence of rheumatoid arthritis is expected to drive the demand for IL-6 inhibitors as a treatment option.
Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-12570
- According to a research article published in National Institute of Health- 2021, the global prevalence of rheumatoid arthritis is estimated to be around 1%.
At present, there are very few pharmacologic inhibitors available in the market approved for commercial and clinical use. However, there are numerous players operating in the market, including Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Eli Lilly and Company among others, who are constantly seeking research and development activities to get more products in the market. This increasing research and development activities in this field are expected to drive the growth of the market.
The rising healthcare expenditure in developed and developing countries is also expected to drive the growth of the Interleukin-6 (IL-6) inhibitors market.
- According to a report by the World Health Organization, global healthcare expenditure is expected to reach US$ 18.3 trillion by 2040. This will ultimately uplift the market.
Key Takeaways:
- By il-6 inhibitor, Tocilizumab segment held a market share of about 43.1% in the global market, in 2022 due to its high efficacy in the treatment of rheumatoid arthritis and other diseases.
- By disease type, rheumatoid arthritis segment held a share of around 47.7% in the global market, in 2022 due to high prevalence of RA and growing usage of interleukin 6 inhibitors for treatment of same.
- By distribution channel, hospital pharmacies held a market share of around 45.8% in 2022 due to presence of skilled doctors and availability of drugs within the hospital premises.
- North America dominated the global market with U.S. contributing around US$ 15.5 Billion in 2022.
Market Competition:
In order to further strengthen their standing in the global market and to increase their presence in new markets, major players in the market are focusing on stepping up their research and development activities. Partnerships and collaborations with research organizations and other companies are the primary strategies used by manufacturers to dominate the market and grow their businesses.
- In 2021, interleukin-6 receptor blockers were suggested by the World Health Organization (WHO) for the treatment of COVID-19, and manufacturers were recommended to join initiatives to hasten access. Also, WHO started a prequalification process for manufacturers of interleukin-6 receptor blockers?
Key Companies:
- Novartis AG
- AbbVie Inc.
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Johnson Johnson Services, Inc.
- F. Hoffmann-La Roche
- Sanofi
- GlaxoSmithKline Plc
- AstraZeneca plc
- Investor AB
- Genentech
Key Segmentation :
By il-6 Inhibitor:
- Tocilizumab
- Siltuximab
- Sylvant
By Disease:
- Rheumatoid Arthritis
- Castleman’s disease
- Cancers
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-12570
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
